Conversely, studies have corroborated that therapeutic administration of monoclonal antibodies against CitH3 substantially ameliorates survival rates in septic mice while mitigating ALI, potentially due to inhibition of CitH3-activated caspase-1-dependent inflammasome pathways. The gene discussed is CASP1; the disease is acute respiratory distress syndrome.